JP2014533938A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014533938A5 JP2014533938A5 JP2014537355A JP2014537355A JP2014533938A5 JP 2014533938 A5 JP2014533938 A5 JP 2014533938A5 JP 2014537355 A JP2014537355 A JP 2014537355A JP 2014537355 A JP2014537355 A JP 2014537355A JP 2014533938 A5 JP2014533938 A5 JP 2014533938A5
- Authority
- JP
- Japan
- Prior art keywords
- melanoma
- cell
- vaccine
- cells
- apoptotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000001441 melanoma Diseases 0.000 claims 19
- 210000004027 cell Anatomy 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 8
- 210000004443 dendritic cell Anatomy 0.000 claims 7
- 102100037850 Interferon gamma Human genes 0.000 claims 6
- 108010074328 Interferon-gamma Proteins 0.000 claims 6
- 230000002886 autophagic effect Effects 0.000 claims 5
- 230000004987 nonapoptotic effect Effects 0.000 claims 5
- 230000004083 survival effect Effects 0.000 claims 5
- 230000005867 T cell response Effects 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 229940115256 melanoma vaccine Drugs 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 108700012813 7-aminoactinomycin D Proteins 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 230000036755 cellular response Effects 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 229960003130 interferon gamma Drugs 0.000 claims 2
- 230000007774 longterm Effects 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 229940030325 tumor cell vaccine Drugs 0.000 claims 2
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 claims 1
- 102000000412 Annexin Human genes 0.000 claims 1
- 108050008874 Annexin Proteins 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 238000011510 Elispot assay Methods 0.000 claims 1
- 102000043131 MHC class II family Human genes 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 claims 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 230000001640 apoptogenic effect Effects 0.000 claims 1
- 238000013096 assay test Methods 0.000 claims 1
- 230000004900 autophagic degradation Effects 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 230000032823 cell division Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940029030 dendritic cell vaccine Drugs 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000016784 immunoglobulin production Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549681P | 2011-10-20 | 2011-10-20 | |
| US61/549,681 | 2011-10-20 | ||
| US201261594304P | 2012-02-02 | 2012-02-02 | |
| US61/594,304 | 2012-02-02 | ||
| PCT/US2012/061294 WO2013059778A2 (en) | 2011-10-20 | 2012-10-22 | Antigen presenting cancer vaccine with gamma interferon |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014533938A JP2014533938A (ja) | 2014-12-18 |
| JP2014533938A5 true JP2014533938A5 (cg-RX-API-DMAC7.html) | 2016-02-25 |
Family
ID=48141460
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537355A Pending JP2014533938A (ja) | 2011-10-20 | 2012-10-22 | γインターフェロンを用いた抗原提示癌ワクチン |
| JP2014537358A Pending JP2014530627A (ja) | 2011-10-20 | 2012-10-22 | 抗原提示癌ワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537358A Pending JP2014530627A (ja) | 2011-10-20 | 2012-10-22 | 抗原提示癌ワクチン |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20140308316A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2768534A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2014533938A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20150016200A (cg-RX-API-DMAC7.html) |
| CN (5) | CN105861437A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2012325758A1 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2852960A1 (cg-RX-API-DMAC7.html) |
| HK (2) | HK1201176A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL232173A0 (cg-RX-API-DMAC7.html) |
| SG (4) | SG11201401632WA (cg-RX-API-DMAC7.html) |
| WO (2) | WO2013059778A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2865830B1 (fr) | 2004-01-30 | 2006-05-19 | Neopost Ind | Systeme d'affranchissement de courrier a mode d'impression externe securise |
| HK1201176A1 (en) * | 2011-10-20 | 2015-08-28 | Neostem Oncology, Llc | Antigen presenting cancer vaccine |
| CN103599528B (zh) * | 2013-12-04 | 2015-08-05 | 深圳市合一康生物科技股份有限公司 | 人树突状细胞疫苗的制备方法 |
| EP3169774A4 (en) * | 2014-07-17 | 2018-04-25 | Brian J. Czerniecki | Manufacturing of multi-dose injection ready dendritic cell vaccines and combination therapy for blocking her2 and her3 |
| WO2017193080A1 (en) * | 2016-05-05 | 2017-11-09 | Nantomics, Llc | Checkpoint failure and methods therefor |
| EP3582793A4 (en) * | 2017-02-17 | 2020-12-16 | Aivita Biomedical, Inc. | METHODS TO IMPROVE TUMOR IMMUNOGENICITY AND COMPOSITIONS FOR AUTOLOGOUS ANTI-CANCER IMMUNOTHERAPEUTICS USING MODIFIED TUMOR CELLS AND MODIFIED DENDRITIC CELLS |
| WO2024107624A1 (en) * | 2022-11-14 | 2024-05-23 | Shattuck Labs, Inc. | Methods of overcoming resistance to checkpoint inhibitor therapies |
| CN118441033B (zh) * | 2024-04-24 | 2025-06-20 | 广西医科大学 | HLA-DPB1*05:01在抗γ干扰素自身抗体所致获得性免疫缺陷筛查中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU669379B2 (en) * | 1992-09-07 | 1996-06-06 | Kyowa Hakko Kirin Co., Ltd. | Humanized antibodies |
| US5874560A (en) * | 1994-04-22 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Melanoma antigens and their use in diagnostic and therapeutic methods |
| EP1056834A2 (en) | 1998-02-20 | 2000-12-06 | The Rockefeller University | Apoptotic cell-mediated antigen presentation to dendritic cells |
| DK1224264T3 (da) | 1999-10-15 | 2010-05-10 | Baylor Res Inst | Anvendelse af allogene cellelinjer til at belaste antigenpræsenterende celler til at fremkomme med immunresponser |
| US7015205B1 (en) * | 1999-10-18 | 2006-03-21 | St. Vincent's Hospital And Medical Center Of New York | Melanoma vaccine and methods of making and using same |
| RU2313365C2 (ru) * | 2001-11-29 | 2007-12-27 | Дандрит Байотек А/С | Фармацевтическая композиция для индукции иммунной реакции у человека |
| GB0130720D0 (en) * | 2001-12-21 | 2002-02-06 | Serono Internat S A | Proteins |
| CN1443778A (zh) * | 2002-03-13 | 2003-09-24 | 上海中信国健药业有限公司 | 一种黑色素瘤相关抗原的单克隆抗体及其用途和药物组合物 |
| US20060140983A1 (en) * | 2004-10-25 | 2006-06-29 | Baylor Research Institute | Dendritic cells loaded with heat shocked melanoma cell bodies |
| WO2007016340A2 (en) * | 2005-07-29 | 2007-02-08 | Providence Health System | Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response |
| WO2007051316A1 (en) * | 2005-11-07 | 2007-05-10 | British Columbia Cancer Agency | Inhibition of autophagy genes in cancer chemotherapy |
| MY160857A (en) * | 2006-02-03 | 2017-03-31 | Malaysian Palm Oil Board | A cancer vaccine |
| KR20090033375A (ko) * | 2006-06-30 | 2009-04-02 | 베일러 리서치 인스티튜트 | Ｇｍ-ｃｓｆ 및 인터페론 알파의 사용에 의해 생성되고 열처리 및 사멸된 암 세포가 로딩된 수지상 세포 |
| AR060424A1 (es) | 2007-04-11 | 2008-06-18 | Consejo Nac Invest Cient Tec | Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento |
| GB0713116D0 (en) * | 2007-07-06 | 2007-08-15 | Therapeutics Ltd E | Treatment of melanoma |
| US20090041792A1 (en) * | 2007-07-19 | 2009-02-12 | Istituto Superiore Di Sanita | Dendritic cells, uses therefor, and vaccines and methods comprising the same |
| HK1201176A1 (en) * | 2011-10-20 | 2015-08-28 | Neostem Oncology, Llc | Antigen presenting cancer vaccine |
-
2012
- 2012-10-22 HK HK15101637.0A patent/HK1201176A1/xx unknown
- 2012-10-22 EP EP12842230.0A patent/EP2768534A4/en not_active Withdrawn
- 2012-10-22 JP JP2014537355A patent/JP2014533938A/ja active Pending
- 2012-10-22 WO PCT/US2012/061294 patent/WO2013059778A2/en not_active Ceased
- 2012-10-22 SG SG11201401632WA patent/SG11201401632WA/en unknown
- 2012-10-22 EP EP12841839.9A patent/EP2768519A4/en not_active Withdrawn
- 2012-10-22 CN CN201610218244.6A patent/CN105861437A/zh not_active Withdrawn
- 2012-10-22 WO PCT/US2012/061306 patent/WO2013059784A1/en not_active Ceased
- 2012-10-22 CN CN201280051799.6A patent/CN103917246A/zh active Pending
- 2012-10-22 KR KR1020147013353A patent/KR20150016200A/ko not_active Withdrawn
- 2012-10-22 CN CN201510706438.6A patent/CN105288602A/zh active Pending
- 2012-10-22 CA CA2852960A patent/CA2852960A1/en not_active Abandoned
- 2012-10-22 CA CA2852967A patent/CA2852967A1/en not_active Abandoned
- 2012-10-22 CN CN201610301904.7A patent/CN105999249A/zh active Pending
- 2012-10-22 SG SG10201602424RA patent/SG10201602424RA/en unknown
- 2012-10-22 JP JP2014537358A patent/JP2014530627A/ja active Pending
- 2012-10-22 HK HK15101635.2A patent/HK1201175A1/xx unknown
- 2012-10-22 KR KR1020147013355A patent/KR20150004791A/ko not_active Withdrawn
- 2012-10-22 CN CN201280051821.7A patent/CN103957925A/zh active Pending
- 2012-10-22 US US14/352,982 patent/US20140308316A1/en not_active Abandoned
- 2012-10-22 AU AU2012325758A patent/AU2012325758A1/en not_active Abandoned
- 2012-10-22 SG SG10201508535RA patent/SG10201508535RA/en unknown
- 2012-10-22 US US14/352,983 patent/US9555058B2/en not_active Expired - Fee Related
- 2012-10-22 AU AU2012325764A patent/AU2012325764A1/en not_active Abandoned
- 2012-10-22 SG SG11201401631VA patent/SG11201401631VA/en unknown
-
2014
- 2014-04-22 IL IL232173A patent/IL232173A0/en unknown
- 2014-04-22 IL IL232172A patent/IL232172A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014533938A5 (cg-RX-API-DMAC7.html) | ||
| JP2014530627A5 (cg-RX-API-DMAC7.html) | ||
| Kumai et al. | Optimization of peptide vaccines to induce robust antitumor CD4 T-cell responses | |
| US9211321B2 (en) | Method for proliferation of antigen-specific T cells | |
| US9492529B2 (en) | Method for priming of T cells | |
| Padte et al. | A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primates | |
| JP2021502414A5 (cg-RX-API-DMAC7.html) | ||
| JP2010514455A5 (cg-RX-API-DMAC7.html) | ||
| Salerno et al. | Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund’s adjuvant, with or without peptide | |
| JP2014514927A5 (cg-RX-API-DMAC7.html) | ||
| Hong et al. | Configuration-dependent presentation of multivalent IL-15: IL-15Rα enhances the antigen-specific T cell response and anti-tumor immunity | |
| SI2102331T1 (sl) | Antitumorsko cepivo, izvedeno iz normalnih kemično modificiranih CD4+ celic | |
| BR112016009402A2 (pt) | Peptídeo, linfócitos t citotóxicos (ltc) ativados, método para sua produção, anticorpo, receptor de células t, ácido nucleico, célula hospedeira, uso dos mesmos, kit, método para produzir uma vacina anticâncer personalizada para um paciente individual | |
| PH12015502638A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| JP2013177430A5 (cg-RX-API-DMAC7.html) | ||
| EA202190587A3 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака | |
| PH12020500433A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| PH12013502174B1 (en) | Vaccine delivery method | |
| CN104379730B (zh) | 使树突细胞成熟的组合物以及用其制备抗原特异性树突细胞的方法 | |
| Aspord et al. | pDCs efficiently process synthetic long peptides to induce functional virus‐and tumour‐specific T‐cell responses | |
| Masuko et al. | Artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP): preparation and immunological analysis of vaccine efficacy | |
| JP2015506698A5 (cg-RX-API-DMAC7.html) | ||
| MX2020011793A (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer. | |
| Yang et al. | HCA587 protein vaccine induces specific antitumor immunity mediated by CD4+ T-cells expressing granzyme B in a mouse model of melanoma | |
| Lin et al. | B16 cell lysates plus polyinosinic-cytidylic acid effectively eradicate melanoma in a mouse model by acting as a prophylactic vaccine |